Group 1 - The company has continued to provide high-quality ophthalmic medical services and has become the only center in Hong Kong offering a comprehensive advanced refractive treatment product portfolio, including LASIK, SMILE, SMILE Pro, SILKTM, and ICL, solidifying its technological leadership in the market [1] - The company's business performance has remained stable, with a gradual recovery in operational performance by the end of 2025, as evidenced by patient visits, new patient appointments, and surgical volumes reaching or exceeding levels from the same period in the past two years [1] - The company ranked first in Hong Kong for ICL surgeries in 2025, achieving the industry's top position for the third consecutive year [1] Group 2 - The company has incurred significant professional fees exceeding HKD 15 million due to ongoing allegations against former directors, which have created a substantial financial burden that could have been allocated to business development and enhancing shareholder returns [1] - The company is committed to efficiently completing the investigation related to the allegations and accelerating the resumption of its shares, allowing management to refocus on executing its long-term strategic priorities [1] - The latest resumption guidance includes various directives such as investigation and rectification guidelines, integrity guidelines, internal control guidelines, corporate governance guidelines, disclosure guidelines, financial reporting guidelines, and compliance with Article 13.24 [2]